Abstracts tagged "registries and rituximab"

Abstract Number: 1607 • 2013 ACR/ARHP Annual Meeting
Two Year Follow-Up On Biologics Use In 13 Centers- Data From The International Registry For Biologics In Systemic Lupus Erythematosus
Ronald F. van Vollenhoven¹, Melinda Mild², Søren Jacobsen³, S. Bernatsky⁴, Daniel J. Wallace⁵, Sang-Cheol Bae⁶, Manuel Ramos-Casals⁷, Francisco J. García-Hernández⁸, R. Ramsey-Goldman⁹, Andrea Doria¹⁰, Marta Mosca¹¹, Michelle A. Petri¹², M Ayala-Gutiérrez¹³, J.G. Hanley¹⁴ and for The SLICC group¹⁵, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²Department of medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, ⁴Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁷Laboratorio de Enfermedades Autoinmunes Josep Font, Hospital Clínic, Barcelona, Spain, ⁸Internal Medicine, Hospital Virgen del Rocío, Sevilla, Spain, ⁹Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology Unit - Department of Medicine, University of Padova, Padova, Italy, ¹¹Rheumatology Unit, University of Pisa, Pisa, Italy, ¹²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ¹³Unidad de Enfermedades Autoinmunes, Servicio de Medicina Interna, Hospital Carlos Haya, Malaga, Spain, ¹⁴Division of Rheumatology, Halifax, NS, Canada, ¹⁵Department of Medicine, the Karolinska Institute, Stockholm, Sweden
Background/Purpose: Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding…
Abstract Number: 806 • 2013 ACR/ARHP Annual Meeting
Risk Of Cancer Recurrence Or New Tumors In RA Patients With Prior Malignancies Treated With Various Biologic Agents
Anja Strangfeld¹, Dagmar Pattloch², Peter Herzer³, Edmund Edelmann⁴, Silke Zinke⁵, Martin Aringer⁶, Joachim Listing⁷ and Angela Zink⁸, ¹Programme Area Epidemiology, German Rheumatism Research Center, a Leipniz Institute, Berlin, Germany, ²Programm Area Epidemiologiy, German Rheumatism Research Center, Berlin, Berlin, Germany, ³University of Munich, Munich, Germany, ⁴Rheumatologist, Bad Aibling, Germany, ⁵Rheumatological Office, Berlin, Germany, ⁶Rheumatology, Medicine III, University Clinical Center Technical University of Dresden, Dresden, Germany, ⁷German Rheumatism Research Center, Berlin, Germany, ⁸German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany
Background/Purpose: If patients with rheumatoid arthritis (RA) have a history of malignancy, the choice of treatment is an important clinical question. The aim is to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].